Signal active
Organization
Contact Information
Overview
F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates.
Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.
About
Biotechnology, Pharmaceutical, Biopharma, Oncology
2006
51-100
Headquarters locations
Europe
Social
N/A
Profile Resume
F-Star Therapeutics headquartered in Europe, operates in the Biotechnology, Pharmaceutical, Biopharma, Oncology sector. The company focuses on Biotechnology and has secured $17.6B in funding across 128 round(s). With a team of 51-100 employees, F-Star Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - F-Star Therapeutics, raised $11.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
8
6
0
$137.3M
Details
5
F-Star Therapeutics has raised a total of $137.3M in funding over 5 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2007 | Seed | 2.0M | ||
2007 | Early Stage Venture | 4.4M | ||
2007 | Early Stage Venture | 8.3M | ||
2010 | Early Stage Venture | 11.5M |
Investors
F-Star Therapeutics is funded by 21 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
TVM Capital | - | FUNDING ROUND - TVM Capital | 11.5M |
Roel Bulthuis | - | FUNDING ROUND - Roel Bulthuis | 11.5M |
F-Star Therapeutics | - | FUNDING ROUND - F-Star Therapeutics | 11.5M |
M Ventures | - | FUNDING ROUND - M Ventures | 11.5M |
Recent Activity
There is no recent news or activity for this profile.